Manel Cascalló
Corporate Officer/Principal en THERIVA BIOLOGICS, INC. .
Perfil
Manel Cascalló is currently the Director General-European Region at Theriva Biologics, Inc. He was previously the Chairman & Chief Executive Officer at VCN Biosciences SL.
He obtained his undergraduate and doctorate degrees from the University of Barcelona.
Cargos activos de Manel Cascalló
| Empresas | Cargo | Inicio |
|---|---|---|
| THERIVA BIOLOGICS, INC. | Corporate Officer/Principal | 23/03/2022 |
Antiguos cargos conocidos de Manel Cascalló.
| Empresas | Cargo | Fin |
|---|---|---|
VCN Biosciences SL
 VCN Biosciences SL Miscellaneous Commercial ServicesCommercial Services Part of Theriva Biologics, Inc., VCN Biosciences SL is a clinical-stage immuno-oncology company based in Barcelona, Spain. The Spanish company focuses on developing the next generation of oncolytic adenoviruses that can obtain clinical activity after systemic administration and remodel the complex matrix in the tumor to allow enhanced spreading of therapeutic molecules and the immune system. VCN Biosciences' lead product, VCN-01, is a unique oncolytic adenovirus being studied in clinical trials for cancers for which there is no cure, including pancreatic carcinoma and retinoblastoma. The company was founded by Ramon Alemany. VCN Biosciences was acquired by Theriva Biologics, Inc. from Grifols SA on March 10, 2022 for $92.02 million. | Director Ejecutivo | - |
Formación de Manel Cascalló.
| University of Barcelona | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| THERIVA BIOLOGICS, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
VCN Biosciences SL
VCN Biosciences SL Miscellaneous Commercial ServicesCommercial Services Part of Theriva Biologics, Inc., VCN Biosciences SL is a clinical-stage immuno-oncology company based in Barcelona, Spain. The Spanish company focuses on developing the next generation of oncolytic adenoviruses that can obtain clinical activity after systemic administration and remodel the complex matrix in the tumor to allow enhanced spreading of therapeutic molecules and the immune system. VCN Biosciences' lead product, VCN-01, is a unique oncolytic adenovirus being studied in clinical trials for cancers for which there is no cure, including pancreatic carcinoma and retinoblastoma. The company was founded by Ramon Alemany. VCN Biosciences was acquired by Theriva Biologics, Inc. from Grifols SA on March 10, 2022 for $92.02 million. | Commercial Services |
- Bolsa de valores
- Insiders
- Manel Cascalló
